The Subject Expert Committee on Covid-19 has approved the “emergency use” of Bharat Biotech’s Covaxin vaccine for children aged between 2-18 years old.Phase-2 and Phase-3 trials of the Covaxin vaccine by Hyderabad-based Bharat Biotech on children below the age of 18 years in the months of September. Trial data was submitted to the Drugs and Comptroller General of India (DCGI) in October 2021.According to AIIMS professor, latest trials suggests that safety and immunogenicity of India’s indigenous COVID-19 vaccine is almost the same in children aged 2-18 years, as it is in adults above 18-years of age.Trial was done by diving children into three groups. The first group was between 12 -18 years, second group was between 6- 12 years while the third age group was between 2-6 years.
How Covaxin was developed?
Your email address will not be published. Required fields are marked *
© Powered By Current Hunt, Designed & Developed By Quizsolver.com
This function has been disabled for Current Hunt.